Skip to content

Discussing an Integrative “AI Mindset”

Join our panel, October 16th, 1:50 PM ET

Register Here

AI-Powered Precision Antibody Therapeutics

Epitope-Steering and Antibody Optimization

About Us

Therapeutic Pipeline

RAPIDLY ADVANCING HARD-TO-ENGINEER ANTIBODIES

Explore

Obesity and Cardiometabolic Conditions

Collaborating to develop first-in-class and best-in-class molecules for obesity, diabetes, and heart disease

Learn More

Immuno-Oncology

Advancing our preclinical pipeline and innovating with our partners to overcome oncology’s discovery and development challenges

Explore More

Partner with iBio

License our discovery platform or collaborate with us to advance our high-value pipeline assets

Contact Us

Discovery Platform

From precision antibody identification and optimization to tailored bispecifics and a cutting-edge masking technology

Platform

Antibody Masking With ShieldTx™

An antibody masking technology for delivering on-epitope, on-tissue clinical candidates with enhanced safety and developability

Learn More

Optimize Bispecifics With EngageTx™

a CD3-BASED T-CELL ENGAGER Platform

Read More

Discovery Platform

A Powerful Tech Stack for Validating Difficult Targets

Discover More

Therapeutic Candidates

Learn how we are deploying our AI Drug Discovery Platform to develop a robust immuno-oncology pipeline

Learn More

Partner With iBio

Where collaboration fuels breakthroughs in drug discovery

Partner With Us

The Expertise Behind the AI

Meet the team driving iBio’s powerful tech stack for drug discovery

Alex Taguchi, Ph.D.

Director, Machine Learning Research & Development

Cody Moore

Associate Director, Platform Development
Meet the Leadership Team

Latest News and Updates

Press Releases

See iBio's latest press releases
Recent Announcements

Register for EndPoints AI Day 2024, Sponsored by iBio

October 16, 2024 11:15 am – 2:30 pm ET
Register Here

iBio in the News

iBio’s Comprehensive Approach to Antibody-Based Therapeutics
Learn More

Join Us for a company presentation at BioFuture, NYC, October 29 11:30 am ET

Martin Brenner, DVM, PhD will discuss iBio’s AI platform and how it has enabled our obesity strategy
Learn More

Accelerating Drug Discovery Through AI and Machine Learning

For Investor inquiries, please visit our Investor Site

Visit Here
Top